Neurological Sciences

, Volume 39, Issue 12, pp 2197–2202 | Cite as

Association between Cystatin C and SVD in Chinese population

  • Huang GuoxiangEmail author
  • Lu Hui
  • Zhou Yong
  • Ji Xunming
  • Chen Zhuo
Original Article


Leukoaraiosis is an important clinical feature of cerebral small vessel disease. To date, there is no reliable biomarker to reflect the degree of cerebral small vessel disease and white matter damage. This study aimed to explore the relationship between cystatin C levels and the degree of white matter damage in order to assess whether cystatin C could serve as a biomarker for white matter damage. We conducted a retrospective analysis of 408 non-critically ill hospitalized patients. The included patients underwent related biochemical and cerebral magnetic resonance imaging examinations. The magnetic resonance imaging results were assessed using the Fazekas scale in fluid attenuation inversion recovery imaging. We analyzed the association of each risk factor (sex, age, blood glucose, blood lipid, and cystatin C) with the degree of white matter damage using univariate logistic and multivariate cumulative odds logistic regression (stepwise). Serum cystatin C concentration was closely associated with the degree of white matter damage (odds ratio = 2.14), while age, sex, and hypertension were associated with selective damage of brain white matter. Triglycerides and apolipoprotein A may have a protective effect against white matter damage.


Leukoaraiosis cystatin C Cerebral small vessel disease Fazekas scale 



This work was supported by the National Natural Science Foundation of China (Grant No.81701286).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Munoz DG (2006) Leukoaraiosis and ischemia: beyond the myth. Stroke 37:1348–1349CrossRefPubMedGoogle Scholar
  2. 2.
    Schmidt R, Petrovic K, Ropele S, Enzinger C, Fazekas F (2007) Progression of leukoaraiosis and cognition. Stroke 38:2619–2625CrossRefPubMedGoogle Scholar
  3. 3.
    Srikanth V, Beare R, Blizzard L, Phan T, Stapleton J, Chen J, Callisaya M, Martin K, Reutens D (2009) Cerebral white matter lesions, gait, and the risk of incident falls: a prospective population-based study. Stroke 40:175–180CrossRefPubMedGoogle Scholar
  4. 4.
    Wardlaw JM, Valdés HMC, Muñoz-Maniega S (2015) What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc 4:001140CrossRefPubMedGoogle Scholar
  5. 5.
    Chutinet A, Biffi A, Kanakis A, Fitzpatrick KM, Furie KL, Rost NS (2012) Severity of leukoaraiosis in large vessel atherosclerotic disease. AJNR Am J Neuroradiol 33:1591–1595CrossRefPubMedGoogle Scholar
  6. 6.
    Curtze S, Haapaniemi E, Melkas S, Mustanoja S, Putaala J, Sairanen T, Sibolt G, Tiainen M, Tatlisumak T, Strbian D (2015) White matter lesions double the risk of post-thrombolytic intracerebral hemorrhage. Stroke 46:2149–2155CrossRefPubMedGoogle Scholar
  7. 7.
    Paciaroni M, Pantoni L (2017) Thrombolysis in dementia patients with acute stroke: is it justified. Neurol Sci 38:27–31CrossRefPubMedGoogle Scholar
  8. 8.
    Smith EE, Schneider JA, Wardlaw JM, Greenberg SM (2012) Cerebral microinfarcts: the invisible lesions. Lancet Neurol 11:272–282CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305CrossRefGoogle Scholar
  10. 10.
    Akoudad S, Sedaghat S, Hofman A, Koudstaal PJ, van der Lugt A, Ikram MA, Vernooij MW (2015) Kidney function and cerebral small vessel disease in the general population. Int J Stroke 10:603–608CrossRefPubMedGoogle Scholar
  11. 11.
    Sedaghat S, Cremers LG, de Groot M, Hoorn EJ, Hofman A, van der Lugt A, Franco OH, Vernooij MW, Dehghan A, Ikram MA (2015) Kidney function and microstructural integrity of brain white matter. Neurology 85:154–161CrossRefPubMedGoogle Scholar
  12. 12.
    Fliser D, Ritz E (2001) Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 37:79–83CrossRefPubMedGoogle Scholar
  13. 13.
    Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, Warram JH (2005) Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 16:1404–1412CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049–2060CrossRefPubMedGoogle Scholar
  15. 15.
    Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG (2007) Association of cystatin C and estimated GFR with inflammatory biomarkers: the heart and soul study. Nephrol Dial Transplant 22:1087–1092CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yaffe K, Lindquist K, Shlipak MG, Simonsick E, Fried L, Rosano C, Satterfield S, Atkinson H, Windham BG, Kurella-Tamura M (2008) Cystatin C as a marker of cognitive function in elders: findings from the health ABC study. Ann Neurol 63:798–802CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yang S, Cai J, Lu R, Wu J, Zhang M, Zhou X (2017) Association between serum Cystatin C level and total magnetic resonance imaging burden of cerebral small vessel disease in patients with acute lacunar stroke. J Stroke Cerebrovasc Dis 26:186–191CrossRefPubMedGoogle Scholar
  18. 18.
    Lee WJ, Jung KH, Ryu YJ, Kim JM, Lee ST, Chu K, Kim M, Lee SK, Roh JK (2017) Cystatin C, a potential marker for cerebral microvascular compliance, is associated with white-matter hyperintensities progression. PLoS One 12:e0184999CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wada M, Nagasawa H, Kawanami T, Kurita K, Daimon M, Kubota I, Kayama T, Kato T (2010) Cystatin C as an index of cerebral small vessel disease: results of a cross-sectional study in community-based Japanese elderly. Eur J Neurol 17:383–390CrossRefPubMedGoogle Scholar
  20. 20.
    Kapeller P, Barber R, Vermeulen RJ, Adèr H, Scheltens P, Freidl W, Almkvist O, Moretti M, del ST, Vaghfeldt P, Enzinger C, Barkhof F, Inzitari D, Erkinjunti T, Schmidt R, Fazekas F (2003) Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke 34:441–445CrossRefPubMedGoogle Scholar
  21. 21.
    Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32:1318–1322CrossRefPubMedGoogle Scholar
  22. 22.
    Wen HM, Mok VC, Fan YH, Lam WW, Tang WK, Wong A, Huang RX, Wong KS (2004) Effect of white matter changes on cognitive impairment in patients with lacunar infarcts. Stroke 35:1826–1830CrossRefPubMedGoogle Scholar
  23. 23.
    Galli A, Di FP, D'Arrigo G, Uggetti C, Squarza S, Leone M, D'Amico D, Frediani F (2017) Migraine with aura white matter lesions: preliminary data on clinical aspects. Neurol Sci 38:7–10CrossRefPubMedGoogle Scholar
  24. 24.
    Kim SH, Shim JY, Lee HR, Na HY, Lee YJ (2012) The relationship between pulse pressure and leukoaraiosis in the elderly. Arch Gerontol Geriatr 54:206–209CrossRefPubMedGoogle Scholar
  25. 25.
    Avet J, Pichot V, Barthélémy JC, Laurent B, Garcin A, Roche F, Celle S (2014) Leukoaraiosis and ambulatory blood pressure load in a healthy elderly cohort study: the PROOF study. Int J Cardiol 172:59–63CrossRefPubMedGoogle Scholar
  26. 26.
    Ho N, Sommers MS, Lucki I (2013) Effects of diabetes on hippocampal neurogenesis: links to cognition and depression. Neurosci Biobehav Rev 37:1346–1362CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lucatelli P, Montisci R, Sanfilippo R, Sacconi B, Suri JS, Catalano C, Saba L (2016) Is there an association between leukoaraiosis volume and diabetes. J Neuroradiol 43:273–279CrossRefPubMedGoogle Scholar
  28. 28.
    Tamura Y, Araki A (2015) Diabetes mellitus and white matter hyperintensity. Geriatr Gerontol Int 15(Suppl 1):34–42CrossRefPubMedGoogle Scholar
  29. 29.
    Yin ZG, Li L, Cui M, Zhou SM, Yu MM, Zhou HD (2014) Inverse relationship between apolipoprotein A-I and cerebral white matter lesions: a cross-sectional study in middle-aged and elderly subjects. PLoS One 9:e97113CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Park K, Yasuda N, Toyonaga S, Yamada SM, Nakabayashi H, Nakasato M, Nakagomi T, Tsubosaki E, Shimizu K (2007) Significant association between leukoaraiosis and metabolic syndrome in healthy subjects. Neurology 69:974–978CrossRefPubMedGoogle Scholar
  31. 31.
    Jimenez-Conde J, Biffi A, Rahman R, Kanakis A, Butler C, Sonni S, Massasa E, Cloonan L, Gilson A, Capozzo K, Cortellini L, Ois A, Cuadrado-Godia E, Rodriguez-Campello A, Furie KL, Roquer J, Rosand J, Rost NS (2010) Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke. Stroke 41:437–442CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Fang Z, Deng J, Wu Z, Dong B, Wang S, Chen X, Nie H, Dong H, Xiong L (2017) Cystatin C is a crucial endogenous protective determinant against stroke. Stroke 48:436–444CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologySecond Affiliated Hospital of Nantong UniversityNantongChina
  2. 2.Department of Neurology, Xuanwu HospitalCapital Medical UniversityBeijingChina

Personalised recommendations